透過您的圖書館登入 IP:3.144.227.72
透過您的圖書館登入
IP:3.144.227.72
  • 精確檢索 : 冠狀病毒
  • 模糊檢索 : 冠狀病毒
  • 冠狀病毒感染
    冠狀病毒疾病
  • 查詢出版品: 冠狀病毒
進階查詢
查詢歷史
主題瀏覽

並列摘要

In the past 7 years, several important antiplatelet trials have been completed with pivotal findings. These results were significant and have been already changing the daily practice of treatment for ischemic stroke (IS). One of the most important findings is the concept of dual antiplatelet therapy for acute noncardioembolic IS or transient ischemic attack. The timing and duration of antiplatelet therapy also have significant impact on the outcomes of IS. In addition to traditional antiplatelets, such as aspirin or clopidogrel, other antiplatelets, including cilostazol, ticagrelor, and prasugrel have also been investigated for the efficacy and safety in the treatment for IS. Another important issue is the use of antiplatelet therapy in primary prevention of cerebro- and cardio-vascular events, the results of several large clinical trials have shown the antiplatelet therapy in specific populations with various estimated risks. The purpose of this current guideline is to update the 2016 Taiwan Stroke Society (TSS) Guideline on Antiplatelet Therapy for Noncardioembolic Ischemic Stroke particularly in areas for which new evidence has emerged since its publication. The TSS Guideline Consensus Group revised the guideline based on the data of several studies which are important and influential. This guideline focuses on three major topics, including secondary prevention, acute management, and primary prevention for noncardioembolic ischemic stroke. Recommendations and reviews of the evidences are provided.

並列關鍵字

acute stroke ； antiplatelet ； ischemic stroke ； noncardioembolic ； prevention

延伸閱讀

全文下載